Mrs Pavletic Aranicki is PregLem’s Chief Executive Officer. She has 20 years of experience in the pharmaceutical industry in both large pharma companies as well as start-up biotech. Mrs Pavletic Aranicki’s skills are in pharmaceutical marketing, commercial operations, business development activities (licensing deals), and raising money via public and private financings. She joined PregLem in 2008 from Merck Serono where she was Global Marketing Director – Reproductive Health. As a VP of Business Development and later Chief Commercial Officer in PregLem she was a member of the management team that lead the company to the successful European registration of Esmya^®, and subsequently its launch in EU. The company was acquired by Gedeon Richter Plc. in 2010.

Mrs. Pavletic holds an MSc in Biotechnology from Zagreb University (Croatia) and an MBA from Webster University in Geneva (Switzerland).

Dr Pablo Arriagada is PregLem’s Vice President Medical Affairs. He is a gynaecologist specialized in Reproductive Endocrinology. He has over 10 year experience in pharmaceutical companies in addition to his clinical experience as a fertility specialist. Dr Arriagada has worked as director of clinical development and medical affairs in both large pharma companies and start-up biotech, holding global and regional positions. His main area of expertise is women’s health.

Dr. Arriagada holds an MD degree from the Catholic University of Chile and a certificate in Management of Biotechnology from EPFL, Lausanne, Switzerland.

Mrs. Vilma Durante is PregLem’s Vice President Global Marketing. She has 25 years of experience in the healthcare industry mainly in Women’s Health. She worked for almost two decades for Serono first and then Merck Serono (now Merck) in different roles of increasing responsibility, both locally and globally, including in the Headquarters where she was Global Strategic Marketing Director for Fertility. Her last assignment, before joining PregLem in January 2016, was at Ferring Pharmaceuticals as Director for Fertility and Obstetrics within the European Commercial Operations.

Mrs. Durante holds a graduate degree in Political Sciences from University of Rome (Italy) La Sapienza.

Mr Jean-Pierre Nkurunziza, Preglem’s Finance Director, has over 10 years’ experience in the fields of finance and accounting in various industries (Consumer products, Energy Trading and Pharmaceuticals) and has served in support function roles in both operational and management capacities. He has also worked on various projects in Finance such as mergers, system migrations and process harmonisation. He joined PregLem in 2013 as Accounting Manager.

Mr Jean-Pierre Nkurunziza is a qualified Chartered Accountant (ACCA), holds a degree in Applied Accounting from Oxford Brooks University in UK and completed a Global MBA in 2015 in Finance Management (from London School of Business and Finance).

Mrs Heike Kenngott is PregLem’s Head of Regulatory Affairs. She has more than 20 years of experience in the pharmaceutical and biotech industry, mainly in Regulatory Affairs.

Heike has been working for many years in the Reproductive Health Therapeutic Area at Serono / MerckSerono, before leading the regulatory team for Endocrinology from 2009-2013. Subsequently she was the Global Regulatory Lead in the Merck Biosimilars Unit before joining PregLem in October 2016.

Heike holds a BSc in Chemical Engineering (FH Isny, Germany) and a MSc in Pharmaceutical Medicine from the University of Surrey (UK).